In Search for an Optimal Solution
Discussing the project of a method of calculation of reference prices for drugs for medicinal use of the Russian MoH, the Experts from the Union of Professional Pharmaceutical Organizations came to a conclusion, that the problem solving approach has generally paid off. However, they remarked, that a number of solutions of the method require review and detailing, and in some cases specification of use.
Pharma manufacturers are concerned with the statements on the maximum level of profitability, as well as the proposal to return from the indicative method of price calculation to the cost-based method.
A letter to the Minister of Healthcare of the Russian Federation Veronika Skvortsova from the Association of Russian Pharmaceutical Manufacturers highlights the risks of switching to the reference pricing for medicinal drugs.
Therefore, the issue of providing patients with all the required and available drugs and maintaining the economic attractiveness for manufacturers is still unresolved.
At the same time, the Federal Antimonopoly Service of the Russian Federation is making efforts to update the State Register of Maximum Manufacturers’ Prices for VED Drugs (Price Register). While noting that the register contains a lot of irrelevant records of prices, which have already been changed, or prices for drugs not marketed in RF, FAS requests that marketing authorization holders (owners) send to the Russian Ministry of Health an application for exclusion from the register of irrelevant register records.